Back to Journals » OncoTargets and Therapy » Volume 11

Prognostic value of miR-17-5p in cancers: a meta-analysis

Authors Kong W, Cheng Y, Liang H, Chen Q, Xiao C, Li K, Huang Z, Zhang J

Received 30 August 2017

Accepted for publication 19 March 2018

Published 19 June 2018 Volume 2018:11 Pages 3541—3549

DOI https://doi.org/10.2147/OTT.S150340

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly


Weihao Kong,* Yusheng Cheng,* Hao Liang,* Qiangxing Chen, Cuicui Xiao, Kun Li, Zenan Huang, Jian Zhang

Department of Liver Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

*These authors contributed equally to this work

Background: Studies have shown that miR-17-5p plays an important role in the development of cancer. The aim of this meta-analysis was to quantitatively analyze the association of miR-17-5p with prognosis in various cancers.
Materials and methods: We searched the PubMed, EMBASE, Web of Science, and Cochrane library databases for relevant studies through August 2017. The prognostic data and clinicopathological features of overall survival (OS) and disease-free survival (DFS) were extracted to investigate the association between miR-17-5p expression and tumor prognosis. In addition, odds ratios (ORs) were used to assess the correlations between miR-17-5p expression and clinicopathological characteristics.
Results: A total of ten studies were incorporated into this systematic review, and we found that high miR-17-5p expression can predict poor OS for malignancies (combined hazard ratio [HR]=1.87; 95% confidence interval [CI], 1.37–2.55; P=0.000) as well as poor DFS (combined HR=1.60; 95% CI, 1.05–2.44; P=0.027). Further subgroup analyses suggested that high miR-17-5p expression was related to poor OS in Asian patients (combined HR=1.92; 95% CI, 1.37–2.71; P=0.000) and the serum/plasma sample source subgroup (combined HR=2.13; 95% CI, 1.36–3.31; P=0.001). The combined OR indicated that the expression of miR-17-5p was associated with lymph node invasion (OR=1.28; 95% CI, 1.05–1.56; P=0.016) and venous invasion (OR=1.92; 95% CI, 1.40–2.63; P=0.000).
Conclusion: Elevated expression of miR-17-5p suggested a poor prognosis in cancer patients and may serve as a new tumor marker to monitor cancer development and progression.

Keywords: miR-17-5p, cancer, prognosis, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]